Colon carcinoma accounts for 20% of deaths due to malignancies in the Western world. Once metastases occur, therapeutic options are limited, with an approximate 5-year survival of only 5%. To investigate the potential of new gene therapeutic approaches, a hepatic micrometastasis model of colon carcinoma in BALB/c mice was established. Inoculation of syngeneic MCA26 colon carcinoma cells into the spleens of 18-to 20-week-old mice resulted in the formation of multiple hepatic metastases. Selective transduction of developing hepatic metastases was demonstrated using a ␤-galactosidase-expressing recombinant adenovirus. Cytosine deaminase (CD) can metabolize 5-fluorocytosine into the chemotherapeutic reagent 5-fluorouracil (5FU). The antitumoral potential of this suicide gene therapy approach was explored by systemic application of a recombinant replication-deficient adenovirus encoding for the bacterial CD gene under the control of the cytomegalovirus promoter (Ad.CMV-CD). Injection into the tail vein of tumor-bearing mice resulted in delayed tumor growth with significant reduction in hepatic metastases. The potential of this experimental approach for possible future clinical applications was evaluated by investigating adenoviral transduction efficiency, 5FU sensitivity, and 5-fluorocytosine-dependent Ad.CMV-CD toxicity in a variety of human colon cancer cell lines. Although the murine cell lines MCA26 and CC36 were highly sensitive to 5FU, the human colon cancer cell lines showed a 1-100 times higher resistance to 5FU. Specific Ad.CMV-CD toxicity correlates with 5FU toxicity. Transduction efficiency in human colon carcinoma cell lines was shown to be 10 -1700 times higher compared with murine cell lines, thus compensating for 5FU resistance. In conclusion, suicide gene therapy using CD may be promising as an adjuvant treatment regimen for hepatic micrometastases of human colon carcinoma. Cancer Gene Therapy (2000) 7, 438 -445
C olorectal cancer accounts for 60,000 fatalities in the United States per year, with ϳ150,000 new cases annually. 1 The majority of patients have metastases to the liver at the timepoint of diagnosis, and half of them will die with metastatic disease confined to the liver only. Surgical resection of hepatic 2 and pulmonary 3 metastases can only be performed in a minority of patients. Current chemotherapy protocols do not substantially improve 5-year survival, which is Ͻ5% once metastases of colorectal cancer have occurred. 4, 5 Systemic application of 5-fluorouracil (5FU) is limited by systemic toxicity. Efforts have been made to reduce systemic toxicity by local application of chemotherapeutic drugs via intraarterial and intratumoral (i.t.) administration. The development of gene transfer techniques provides new possibilities in the treatment of colorectal malignancies. The introduction of suicide genes into tumor tissue enables toxification of nontoxic prodrugs within the tumor. The bacterial enzyme cytosine deaminase (CD) was characterized in Escherichia coli 6 and first evaluated for therapeutic approaches in cancer therapy by Huber et al. 7 CD, which is not found in the human body, has the unique metabolic capability of converting cytosine into uracil. This enzymatic activity can be used to metabolize the nontoxic prodrug 5-fluorocytosine (5FC) into the well-characterized chemotherapeutic reagent 5FU. Adenoviral gene therapy, with its high transduction efficiency in vitro as well as in vivo, has been used to import the CD gene into tumor cells, where the prodrug 5FC is converted to the toxic metabolite 5FU.
MATERIALS AND METHODS

Synthesis of CD-expressing adenoviruses
The construction of recombinant adenoviruses is based on a protocol published by Bett and colleagues, 8, 9 using a twoplasmid system containing the necessary adenoviral information and homologous recombination in a transformed kidney cell line (293 cells). The therapeutic gene replaces the E1 region, which is essential for adenoviral replication. Additional deletion of the E3 region provides further safety in terms of replication deficiency. After cotransfection of the two plasmids, the replication-deficient vector is amplified in 293 cells, providing the lacking E1 gene product. To construct an adenovirus expressing CD, primers were designed (Fig 1) to amplify a fragment containing the CD gene with changes in the start codon suitable for eukaryotic systems as well as the introduction of a Kozak 10 consensus sequence and unique restriction sites for further construction of the expression vector. The primer sequences were 5Ј-CGCAAGCTTGC-CGCCACCATGTCGAATAACGCTTTACAA-3Ј and 3Ј-AT-GTTTGCAACTTGCTGACCTAGGGTC-5Ј. The amplified fragment was cloned into the multiple cloning site of pAd1/ CMVbpA, a plasmid containing the cytomegalovirus (CMV) promoter as well as flanking adenovirus 5 gene fragments necessary for the generation of recombinant replication-deficient adenoviruses by coprecipitation with pBHG10. The construct pAd.CMV-CD was tested for functional CD expression through calcium precipitation in 293 cells, 11 and the transduced cells were incubated with 5FC (Fig 2) . Adenoviruses expressing CD for further studies in vitro and in vivo were synthesized by coprecipitation with pBHG10 in 293 cells, followed by plaque purification and amplification. ␤-galactosidase (␤-gal)-expressing replication-deficient adenoviruses under the control of the Rous sarcoma virus long terminal repeat promoter (Ad.RSV-␤-gal) as well as the replication-deficient control virus Ad.DL312, containing an empty expression cassette, were prepared as described previously. 12 
Adenoviral transduction efficiency in vitro
The adenoviral transduction efficiency of the murine as well as the human colon cancer cell lines was evaluated in vitro using the replication-deficient ␤-gal marker gene expressing adenovirus Ad.RSV-␤-gal (a gift from M. Perricaudet, Institut Gustave Roussy Villejvif Cedex, France).
As described previously, 13 murine colon cancer cells were seeded in 6-vial tissue culture plates (10 5 cells in 2 mL of complete media) and incubated at 37°C and 5% CO 2 for 6 hours. Cells were then incubated with Ad.RSV-␤-gal at different multiplicities of infection (MOIs) ranging from 0 to 3000 in serum-free media after washing with phosphate-buffered saline (PBS). After incubation for 1 hour, media were replaced by regular growth media, and cells were incubated for another 48 hours. Cells were then washed twice with ice-cold PBS containing 0,5% glutaraldehyde. To determine ␤-gal activity, cells were incubated with a staining solution containing 1.3 mM MgCl 2 , 3 mM NaCl 2 , 3 mM potassium ferricyanide, 3 mM potassium ferrocyanide, 0.5 mg/mL 5-bromo-4 chloro-3-indolyl-␤-galactoside (X-Gal), and 44 mM N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid (pH 7.3). The ratio of transduced cells was quantified by determination of the percentage of blue nuclei, because ␤-gal activity occurred in the nucleus due to a nuclear translocation signal. Functional assay for the CD-expressing adenoviral expression plasmid pAd.CMV-CD. After calcium phosphate-mediated precipitation, the 293 cells were incubated in the presence of various doses of 5FU or 5FC. Although 293 cell proliferation was not sensitive to 5FC after precipitation with a control plasmid (pRC. CMV-␤-gal), precipitation with pAd.CMV-CD resulted in 5FC-mediated inhibition of proliferation that was comparable with inhibition by 5FU.
Ad.CMV-CD transduction and CD-mediated 5FC toxicity in vitro
The CD-mediated toxicity of 5FC in transduced colon cancer cells has been evaluated using an in vitro proliferation assay. 14 -16 Viable cells metabolize 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) into formazan, a blue dye that can be quantified photospectrometrically. A total of 1.5 ϫ 10 3 human or murine colon cancer cells were seeded in 75 L of complete media in 96-vial plates and incubated for 6 hours at 37°C. Cells were then incubated with different MOIs of Ad.CMV-CD in 56 L of serum-free media per vial. After 12 hours, 5FC at a final concentration of 1000 M or PBS was added, and incubation was continued for an additional 48 hours. Finally, tumor cell proliferation was quantified by adding 37.5 L of MTT solution (1 mg/mL in Dulbecco's modified Eagle's medium) and incubating for 4 hours at 37°C. After the medium was removed, the formazan product was dissolved in 150 L of dimethylsulfoxide and quantified using a microtiter plate reader at 595 nm.
Establishing a colon cancer micrometastasis model in mice
To evaluate the potential of the CD suicide system in vivo, we established an animal model by intrasplenic inoculation of syngeneic MCA26 colon cancer cells. After anesthesia with 0.5 mg 2,2,2-tribromoethanol (Avertin) per gram of bodyweight intraperitoneally (i.p.), spleens were exposed by a left lateral incision, and injections were placed into the caudal tip of the spleen. To avoid i.p. bleeding and leakage of tumor cells, the injection sites were ligated with catgut. After 24 hours, the mice were reanesthetized with Avertin, splenectomies were performed by medial incisions, and major splenic vessels were ligated. Accessory splenic vessels were electrocoagulated, and the abdominal incisions were closed by stapling. We initially investigated the tumorigenicity of intrasplenically applied MCA26 colon cancer cells. Survival of 8-to 10-week-old female BALB/c mice after splenic injection of MCA26 cells and consecutive splenectomy depended upon the number of injected tumor cells. The required tumor cell dosage for the formation of tumors was between 1,000 and 10,000 cells. Mean survival varied from 10 days (10 6 cells) to 40 days (10 4 cells). Most of the injected cells drained through the splenic vein and formed multiple hepatic metastases. With further tumor progression, mice died of hepatic failure. After the establishment of hepatic metastases, pulmonary metastases occurred. No other sites of metastases were found after splenectomy. All of the following experiments were performed with 10 5 cells injected into the spleen. For evaluation of the adjuvant treatment of hepatic colon carcinoma metastases, the toxicity of systemically applied Ad.CMV-CD adenovirus in combination with 5FC was investigated. Increasing dosages of recombinant CD-expressing adenoviruses were injected through the tail vein, and the mice were then treated with an i.p. injection of 5FC (500 mg/kg body weight, twice daily for 10 days). We demonstrated that 3 ϫ 10 7 plaque-forming units (PFU) was a safe dose, causing no fatalities or any significant morbidity (n ϭ 5).
Adenoviral transduction in vivo
After intrasplenic administration of 10 5 MCA26 tumor cells and splenectomy the following day as described previously, a dose of 10 9 PFU of Ad.RSV-␤-gal in 200 L of buffer containing 10 mM tris(hydroxymethyl)aminomethane, 1 mM MgCl 2 , 20 g/mL polybrene, and 10% (vol/vol) glycerol (pH 7.4) was applied without prior anesthesia through the tail vein at 48 hours after tumor cell injection. After 12 days, when intrahepatic tumor formation became visible, livers were removed after anesthesia with 0.5 mg/kg bodyweight 2,2,2-tribromoethanol (Avertin). The livers were stained directly after fixation for 2 hours in PBS (pH 7.3) containing 1% formaldehyde and 0.2% glutaraldehyde. The hepatic tissues were then incubated in a PBS solution containing 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, 2 mM magnesium chloride, and 1 mg/mL X-Gal for 4 hours at 37°C. For histochemical analysis of transduction, the livers were cryoconserved, cut, stained for ␤-gal as well as hematoxylineosin, and counterstained according to previous publications. 17, 18 Gene therapy of colon cancer metastases to the liver After 48 hours of intrasplenic tumor cell injection and at 24 hours after splenectomy, mice received varying dosages of either Ad.CMV-CD, the control adenovirus Ad.DL312, or PBS (diluted in 200 L of buffer containing 10 mM tris(hydroxymethyl)aminomethane, 1 mM MgCl 2 , 20 g/mL polybrene, and 10% (vol/vol) glycerol (pH 7.4)) through the tail vein. 5FC was dissolved in calcium-free PBS and administered i.p. (500 L) once daily for 10 days at a dose of 500 mg/kg bodyweight. Mice were maintained for long-term survival and observed for symptoms of tumor progression (activity, weight loss, fleeing reaction) twice per day. At the timepoint of death, livers were removed and analyzed further.
Macroscopic pathology, histopathology, and survival
Visible metastases on the liver surface were counted, and livers were preserved in PBS containing 10% formaldehyde for further hematoxylin-eosin staining. Survival was analyzed using the Mantel-Cox log-rank test (Statview software package, Abacus Concepts, Berkeley, Calif).
All animal experiments conducted in this study were performed according to the National Institutes of Health Guidelines for the Use and Care of Laboratory Animals
RESULTS
In vitro transduction of MCA26 and adenoviral toxicity
Transduction efficiency of the murine MCA26 colon carcinoma cell line was demonstrated in vitro using ␤-gal-expressing recombinant adenoviruses and X-Gal staining after adenoviral transduction (Fig 3) . At a PFU-based MOI of 2566, 50% visible transduction of MCA26 tumor cells was obtained. Subsequently, MCA26 cells were transduced with Ad.CMV-CD in vitro and incubated in the presence of 5FC to investigate the antitumoral capacity of this suicide system in vitro (Fig 4) . Although the adenovirus alone did not exhibit a significant inhibition of proliferation, a concentration of 105 MOI in combination with 5FC showed a 50% decrease in proliferation. 5FC alone had no effect on the proliferation tested in a variety of colon cancer cell lines (data not shown).
In vivo transduction
Adenoviral transduction efficiency in vivo was analyzed using a ␤-gal-expressing adenovirus (Ad.RSV-␤-gal, 10 9 PFU), injected through the tail vein 24 hours after splenectomy and 48 hours after splenic injection of MCA26 colon cancer cells. When micrometastases became visible after 14 days (cell dosage 10 5 ), the livers were removed and stained to visualize viral transduction (Fig 5A) . Histochemistry revealed exclusive i.t. transduction (Fig 5B) .
In vivo toxicity and efficiency
A dose-escalation study was performed to determine the maximum tolerable dose of Ad.CMV-CD, which was applied through the tail vein in the presence of 5FC (500 mg/kg/day i.p. 's t test) ).
Survival (Fig 8) seemed to be slightly but not significantly improved in the treatment group (a) compared with the control groups (b and c) (P ϭ .0993), indicating that CD suicide gene therapy may be useful as an adjuvant treatment modality of hepatic metastasis of human colon cancer. To evaluate the potential of this strategy in a possible clinical setting, we analyzed a variety of human cancer cell lines in terms of transduction efficiency, 5FU sensitivity, and acquired 5FC sensitivity after transduction with Ad.CMV-CD.
Human colon cancer cell lines: In vitro transduction and 5FU sensitivity
A variety of human colon cancer cell lines were characterized according to adenoviral transduction efficiency. The human cancer cell lines T84, HT29, SkCo-1, HCT116, Lovo, Colo205, Colo320, Colo620, and WiDr were received from the American Type Culture Collection (Manassas, Va); in vitro transduction of these cell lines was performed as described previously. Transduction efficiency, described as the MOI required for 50% visible transduction of tumor cells, is shown in Figure 9 . Transduction efficiency was correlated with basic 5FU sensitivity. Basic 5FU sensitivity was determined by incubating colon cancer cell lines with varying concentrations of 5FU to estimate the concentration required for 50% inhibition of proliferation (M) (based on the MTT proliferation assay).
The transduction efficiency of human colon cancer cell lines using the human-pathogenic adenovirus Ad.RSV-␤-gal was in the range of 1.7-239 MOIs with an MOI of Ͻ11 in eight of nine human colon cancer cell lines. Transduction efficiency was 10-to 1700-fold higher in human cell lines compared with murine colon cancer cell lines. The murine cell lines MCA26 and CC36 were very sensitive to incubation with 5FU. Concentrations of 1.05 and 1.25 M, respectively, resulted in a 50% inhibition of proliferation. Human colon cancer cell lines showed wide variations in terms of sensitivity, from very sensitive cell lines (Colo320, 1.20 M) to resistant cell lines (T84, 220 M).
Transduction efficiency correlated with prodrug-independent adenoviral toxicity (r 2 ϭ 0.991), as demonstrated by inhibition of proliferation after incubation with various ratios of Ad.CMV-CD in the absence of the prodrug 5FC (data not shown). In the absence of the correlating prodrug, basic adenoviral toxicity was independent of the suicide gene used.
Prodrug-dependent, specific adenoviral toxicity was determined as the ratio of adenoviral toxicity in the presence and absence of the prodrug. This ratio was correlated with the in vitro sensitivity of colon cancer cell lines to 5FU (Fig 10) . Ratios for human colon cancer cell lines range from a 34.7-fold increase of sensitivity in the presence of 5FC for Colo320 to only 1.2-, 2.0-, 2.3-, and 2.5-fold for Lovo, HCT116, Colo620, and T84. 
DISCUSSION
Because early colorectal cancer causes either no symptoms or very unspecific symptoms, synchronous hepatic metastases of colon cancer at the time of diagnosis occur in 10 -15% of all colon cancer patients. 19 Once metastasis has occurred, therapeutic options are poor, and long-term survival rates remain dismal. Current chemotherapeutic protocols are limited by systemic toxicity, and response rates are ϳ20 -30% without prolonged survival in metastatic colorectal cancer. 20 Several approaches have been undertaken to reduce systemic toxicity by local application. Intrahepatic artery chemotherapy resulted in response rates of 40 -80% with no significant improvement of survival. 21 A recent development in cancer gene therapy has enabled i.t. gene expression, promising a more effective approach with reduced systemic toxicity. Suicide genes such as thymidine kinase have already been investigated in a series of preclinical colon cancer studies. 22, 23 Dose-escalation studies of replication-deficient thymidine kinase suicide gene-expressing vectors (our unpublished data) revealed a dose-dependent significant hepatotoxicity, indicating that these vectors are not suitable for systemic administration to treat multiple hepatic metastases. CD, which was characterized in 1992 and evaluated soon afterward for its potential in suicide gene therapy, 6, 7, 24 metabolizes 5FC into 5FU. 5FU has a short half-life of 8 -14 minutes, 25 due to intrahepatic metabolization, 26 and the advantage of low hepatotoxicity. The use of replication- deficient adenoviruses rather than retroviruses as vectors in cancer gene therapy has the advantage of high viral titers and a high transduction efficiency 27, 28 as well as apparent safety in clinical trials. 29 The multiple hepatic metastases model was preferred over the previously published single hepatic tumor model, 13, 22, 30, 31 because multiple hepatic metastases after intrasplenic colon cancer cell injection appear to replicate the clinical setting more closely, especially when addressing questions such as toxicity and potential efficiency after systemic administration of adenoviral vectors. A syngeneic tumor model was chosen because the immune competence of the host potentially has an impact on the efficiency of suicide gene therapy approaches. Also, repeated surgical interventions such as intrasplenic tumor cell administrations and splenectomies in immune-incompetent mice imply a much higher risk of bacterial infections and related fatalities.
The In vitro transduction efficiency of the murine colon cancer cell line MCA26 was 10-to 1700-fold lower compared with a variety of human colon cancer cell lines. The higher transduction efficiency in human cell lines is explained by the interaction of a human pathogenic adenovirus, Ad5, with specific receptors. The primary Coxsackievirus and adenovirus receptor 32, 33 and the secondary AdV receptor, a member of the integrin family of surface molecules, 34, 35 have been characterized recently.
Systemic administration of ␤-gal-expressing adenovi- ruses at 48 hours after intrasplenic tumor cell injection and at 24 hours after splenectomy resulted in exclusive transduction of MCA26 colon cancer cells. This finding was surprising considering the localization of the majority of ␤-gal-expressing adenoviruses in hepatic tissue after systemic administration in non-tumor-bearing mice. 36 This finding could be reproduced by applying the adenovirus intravenously 12 days after intrasplenic tumor cell injection. At this time, hepatic colon cancer metastases were already visible, and X-Gal staining was restricted to the hepatic parenchyma. Obviously, the transduction efficiency and adenoviral receptor status in vivo depend not only upon the injected tumor cell line but also upon the developmental stage of hepatic metastases at the timepoint of systemic adenoviral delivery. The dependence of adenovirus receptor expression upon tumor development is currently under investigation.
I.t. CD gene expression in the presence of 5FC resulted in a significant reduction in hepatic metastases. Considering the low transduction efficiency of the murine colon cancer cell line MCA26 used for this in vivo study, this approach might be even more promising as a neoadjuvant treatment regimen for potentially metastasized colon cancer in humans.
The high transduction efficiency of human colon cancer cell lines may also override acquired or innate 5FU resistance, as shown in Figure 10 . As expected, prodrugdependent CD adenoviral toxicity correlated with 5FU sensitivity. However, the 5FU-resistant cell line SkCo-1 exhibited high prodrug-dependent sensitivity to Ad-.CMV-CD, assuming that 5FU resistance could be compensated for by high transduction efficiency in vitro. The sensitive cell lines HCT116 and Lovo were highly transducible, and consequently already showed a high prodrug-independent adenoviral sensitivity. This might explain the moderate increase in sensitivity of only 1.2-and 2.0-fold in the presence of 5FC. In vivo studies with human colon cancer cell lines in athymic mice will address the issue of overriding 5FU resistance through i.t. overexpression of the CD gene in the presence of 5FC.
These data also emphasize the need to develop conditionally replication-competent vectors that can be targeted to the tumor cells, given that replication in vivo can be precisely controlled to comply with current biosafety standards in gene therapy. Figure 10 . Correlation of 5FU sensitivity versus 5FC-dependent specific Ad.CMV-CD sensitivity in human and murine colon carcinoma cell lines in vitro. Sensitivity is defined as the inhibition of proliferation by 50%.
